Nu-Med Plus, Inc. (OTC:NUMD)
| Market Cap | $902.32K-55.6% |
| Revenue (ttm) | $0-100.0% |
| Net Income | -$20.79K+65.8% |
| EPS | -$0.00+50.0% |
| Shares Out | 83.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,000 |
| Open | $0.01 |
| Previous Close | $0.01 |
| Day's Range | $0.01 - $0.01 |
| 52-Week Range | $0.01 - $0.03 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NUMD
Nu-Med Plus, Inc. is a global medical technology firm dedicated to the innovation, refinement, and commercialization of various medical instruments. The company's offerings include a diverse array of nitric oxide delivery systems, such as specialized units for hospital environments, clinical applications, and research settings, alongside a mobile, rechargeable device designed for portable nitric oxide gas administration. Serving a broad spectrum of healthcare entities, its primary clients consist of hospitals, integrated health systems, and the wider medical professional community. Nu-Med Plus, Inc. was founded in 2011 and maintains its corporate headquarters in Salt Lake City, Utah.
$NUMD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NUMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NUMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NUMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NUMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NUMD from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from NUMD’s recent data — informational, not investment advice
